Skip to content

Influence of Daylong Glycemia on Detraining Induced Metabolic Changes

Einfluss Der Postprandialen Glykämie Auf Inaktivitäts-induzierte Veränderungen im Stoffwechsel

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02321033
Enrollment
16
Registered
2014-12-22
Start date
2014-08-31
Completion date
2015-09-30
Last updated
2015-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

glycemic index, inactivity, insulin sensitivity, metabolic flexibility, arterial stiffness, young men

Brief summary

Aim of the study is to investigate the impact of glycemic index (provided as soft drinks) on changes in insulin sensitivity, metabolic flexibility, and arterial stiffness in response to detraining. The investigators hypothesize that low glycemic soft drinks decrease the detraining-induced impairment of insulin sensitivity, metabolic flexibility and arterial stiffness.

Detailed description

The duration of the study is 7 weeks: two x 2 weeks intervention (phase A and phase B) with 3 weeks washout phase inbetween. Each 2-week intervention phase consists of an active week followed by an inactive week. in phase A subjects consume high GI (maltodextrin and sucrose) soft drinks during the inactive week. In phase B subjects consume a low GI soft drink (palatinose) during the inactive week. subjects were randomly assigned to either start with phase A or with phase B (cross over design). During the whole study duration all food is provided (55% CHO, 30% fat, 15% protein) Physical activity will be assessed by a step counter (active phase 7000-10000 steps/d and inactive phase 3000-4000 steps/d).

Interventions

DIETARY_SUPPLEMENTsoft drinks

soft drinks with palatinose and maltodextrin

Sponsors

University of Hohenheim
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* normal weight men, * age 18-35 y, * active life style, * \> 300 min sports/week

Exclusion criteria

* food allergies, * regular use of medication, * smoking, * chronic disease, * vegan/vegetarian diet

Design outcomes

Primary

MeasureTime frameDescription
Influence of GI on inactivity-induced changes in insulin sensitivity as measured by an OGTTthe difference between the end of each 1 week activity phase (day 7 vs. day 14, low vs. high physical activity) is compared between high GI and low GI interventionInfluence of GI (glycemic index) on detraining-induced changes (difference between the end of high activity and low activity phases) in insulin sensitivity Insulin sensitivity is assessed by HOMA and Matsuda indices

Secondary

MeasureTime frameDescription
Influence of GI on inactivity-induced changes in metabolic flexibility as measured by indirect calorimetry (RER, respiratory exchange ratio)the difference between the end of each 1 week activity phase (day 7 vs. day 14) is compared between high GI and low GI interventionImpact of GI on inactivity induced changes in metabolic flexibility Metabolic flexibility is defined as the body´s ability to adapt fuel oxidation to changing fuel availability and energy demand It is measured as change in fasting RER (fasting metabolic flexibility) and change in RQ (difference between the end of high activity and low activity phases) after an oral glucose tolerance test (postprandial metabolic flexibility)

Other

MeasureTime frameDescription
Influence of GI on inactivity-induced changes in parameters of arterial stiffness as measured by pulse wave velocitythe difference between the end of each 1 week activity phase (day 7 vs. day 14) is compared between high GI and low GI interventionimpact of GI on inactivity-induced changes (difference between the end of high activity and low activity phases) in arterial stiffness (as assessed by pulse wave velocity)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026